Q4 2025 Option Care Health Inc Earnings Call Transcript
Key Points
- Option Care Health Inc (OPCH) reported a 13% increase in net revenue for 2025, reaching $5.6 billion, driven by balanced growth across acute and chronic therapies.
- The company served over 315,000 unique patients and completed over 2.5 million infusion events in 2025, highlighting its extensive reach and service capability.
- Option Care Health Inc (OPCH) expanded its formulary and added new infusion suites and pharmacies, enhancing its service offerings and market presence.
- The company achieved a 7.4% growth in gross profit dollars and reduced its SG&A as a percentage of sales by 50 basis points, reflecting improved efficiency.
- Option Care Health Inc (OPCH) continues to invest in technology, including AI, to automate key functions, with 40% of claims processed without human intervention, improving efficiency and productivity.
- The adoption of Stelara biosimilars resulted in a 160 basis point revenue headwind, impacting the chronic portfolio.
- Option Care Health Inc (OPCH) faced a $25 million to $35 million gross profit headwind related to Stelara and Stelara biosimilars conversion, expected to impact 2026 evenly.
- Operating cash flow for 2025 was below prior guidance, finishing at $258 million due to strategic inventory buys and increased working capital for limited distribution therapies.
- The company anticipates a 400 basis point revenue growth headwind in 2026 due to Stelara IRA and Stelara biosimilars conversion.
- Despite strong performance, Option Care Health Inc (OPCH) faces ongoing economic pressures in the healthcare industry, including rising healthcare costs and rate pressures for Medicare Advantage exposure.
Good day, and thank you for standing by. Welcome to the Option Care Health fourth-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Nicole Maggio, Senior Vice President of Finance. Please go ahead.
Good morning. Please note that today's discussion will include certain forward-looking statements that reflect our current assumptions and expectations, including those related to future financial performance and industry and market conditions. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from our expectations. We encourage you to review the information in today's press release as well as in our Form 10-K filed with the SEC regarding the specific risks and uncertainties. We do not undertake any duty to update any forward-looking
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
